Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned an average rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $13.80.

A number of brokerages have recently issued reports on AMRX. Truist Financial set a $15.00 target price on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Barclays assumed coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price for the company.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the sale, the director owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares in the company, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 231,856 shares of company stock valued at $2,743,724. Insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AMRX. Assenagon Asset Management S.A. raised its holdings in shares of Amneal Pharmaceuticals by 75.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after purchasing an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC bought a new position in Amneal Pharmaceuticals during the third quarter valued at about $13,833,000. Allspring Global Investments Holdings LLC raised its holdings in Amneal Pharmaceuticals by 1,440.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock valued at $11,790,000 after buying an additional 1,062,045 shares in the last quarter. Rubric Capital Management LP lifted its position in shares of Amneal Pharmaceuticals by 9.1% in the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after buying an additional 974,355 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Amneal Pharmaceuticals by 2,866.0% during the 4th quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock worth $9,889,000 after acquiring an additional 758,343 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $13.41 on Monday. The firm has a market cap of $4.22 billion, a PE ratio of 670.84 and a beta of 1.34. Amneal Pharmaceuticals has a 12 month low of $6.68 and a 12 month high of $13.48. The firm has a 50 day simple moving average of $12.42 and a 200 day simple moving average of $10.49.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, sell-side analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.